Since the low expression of SOX17 in ESCC is attributed to promoter hypermethylation [23], we then examine whether DNA methyltransferases DNMT1 and DNMT3B could be affected by ZVI@CMC treatment. The gene discussed is SOX17; the disease is esophageal squamous cell carcinoma.